Statins impair glucose uptake in tumor cells

Neoplasia

Volumn 14, Issue 4, 2012, Pages 311-323

  Malenda, Agata ^a   Skrobanska, Anna ^a   Issat, Tadeusz ^a   Winiarska, Magdalena ^a   Bil, Jacek ^a   Oleszczak, Bozenna ^a   Sinski, Maciej ^b   Firczuk, Małgorzata ^a   Bujnicki, Janusz M ^c,d   Chlebowska, Justyna ^a   Staruch, Adam D ^a   Glodkowska Mrowka, Eliza ^a   Kunikowska, Jolanta ^b   Krolicki, Leszek ^b   Szablewski, Leszek ^a   Gaciong, Zbigniew ^b   Koziak, Katarzyna ^b   Jakobisiak, Marek ^a   Golab, Jakub ^a,e   Nowis, Dominika A ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^d ADAM MICKIEWICZ UNIVERSITY   (Poland)

^e INSTITUTE OF PHYSICAL CHEMISTRY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; F ACTIN; FLUINDOSTATIN; FLUORODEOXYGLUCOSE F 18; G ACTIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTIC ACID; MEVINOLIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BIOTINYLATION; CASE REPORT; CELL CYCLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MANTLE CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPEATED DRUG DOSE; TUMOR CELL; WESTERN BLOTTING;

EID: 84860609577     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12444     Document Type: Article

References (52)

1. Levine AJ and Puzio-Kuter AM (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344.
2. Cairns RA, Harris IS, and Mak TW (2011). Regulation of cancer cell metabolism. Nat Rev Cancer 11, 85-95.
3. Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, and Overgaard J (2008). Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 122, 2726-2734.
4. Gillies RJ and Gatenby RA (2007). Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 39, 251-257.
5. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, and Kotsuji F (2004). Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109, 926-932.
6. 18F-FDGuptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J NuclMed 45, 22-29.
7. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, Ohshio G, Hosotani R, Imamura M, and Konishi J (1997). Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 38, 1337-1344.
8. Augustin R (2010). The protein family of glucose transport facilitators: it's not only about glucose after all. IUBMB Life 62, 315-333.
9. Furuta E, Okuda H, Kobayashi A, and Watabe K (2010). Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 1805, 141-152.
10. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, et al. (2010). Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28, 3746-3753.
11. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, et al. (2002). Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20, 379-387.
12. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, et al. (2009). 18F fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 27, 2697-2704.
13. Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, et al. (2008). Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 5, e64.
14. Dimitroulakos J and Yeger H (1996). HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 2, 326-333.
15. Allsopp RC, Lalo U, and Evans RJ (2010). Lipid raft association and cholesterol sensitivity of P2X1-4 receptors for ATP: chimeras and point mutants identify intracellular amino-terminal residues involved in lipid regulation of P2X1 receptors. J Biol Chem 285, 32770-32777.
16. Hinzpeter A, Fritsch J, Borot F, Trudel S, Vieu DL, Brouillard F, Baudouin-Legros M, Clain J, Edelman A, and Ollero M (2007). Membrane cholesterol content modulates ClC-2 gating and sensitivity to oxidative stress. J Biol Chem 282, 2423-2432.
17. Harikumar KG, Puri V, Singh RD, Hanada K, Pagano RE, and Miller LJ (2005). Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem 280, 2176-2185.
18. Fantini J and Barrantes FJ (2009). Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. BiochimBiophys Acta 1788, 2345-2361.
19. Paila YD, Tiwari S, Sengupta D, and Chattopadhyay A (2011). Molecular modeling of the human serotonin(1A) receptor: role of membrane cholesterol in ligand binding of the receptor. Mol Biosyst 7, 224-234.
20. O'Malley MA, Helgeson ME, Wagner NJ, and Robinson AS (2011). The morphology and composition of cholesterol-rich micellar nanostructures determine transmembrane protein (GPCR) activity. Biophys J 100, L11-L13.
21. Baier CJ, Fantini J, and Barrantes FJ (2011). Disclosure of cholesterol recognition motifs in transmembrane domains of the human nicotinic acetylcholine receptor. Sci Rep 1, 69.
22. Kaliman P, Vinals F, Testar X, Palacin M, and Zorzano A (1995). Disruption of GLUT1 glucose carrier trafficking in L6E9 and Sol8 myoblasts by the phosphatidylinositol 3-kinase inhibitor wortmannin. Biochem J 312(pt 2), 471-477.
23. Tchou J, Sonnad SS, Bergey MR, Basu S, Tomaszewski J, Alavi A, and Schnall M (2010). Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol 12, 657-662.
24. Vander Heiden MG, Cantley LC, and Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
25. Huang S and Czech MP (2007). The GLUT4 glucose transporter. Cell Metab 5, 237-252.
26. Mahammad S, Dinic J, Adler J, and Parmryd I (2010). Limited cholesterol depletion causes aggregation of plasma membrane lipid rafts inducing T cell activation. Biochim Biophys Acta 1801, 625-634.
27. Buhaescu I and Izzedine H (2007). Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40, 575-584.
28. Wang CY, Liu PY, and Liao JK (2008). Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14, 37-44.
29. Liao JK and Laufs U (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45, 89-118.
30. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359, 2195-2207.
31. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, et al. (2001). Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357-362.
32. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, et al. (2010). Statins and risk of incident diabetes: a collaborativemeta-analysis of randomised statin trials. Lancet 375, 735-742.
33. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, et al. (2011). Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305, 2556-2564.
34. Guyton JR (2007). Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18, 415-420.
35. Basso AD, Kirschmeier P, and Bishop WR (2006). Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47, 15-31.
36. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, and Hommel U (2001). Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7, 687-692.
37. Marcoff L and Thompson PD (2007). The role of coenzyme Q10 in statinassociated myopathy: a systematic review. J Am Coll Cardiol 49, 2231-2237.
38. Haeuptle MA, Hulsmeier AJ, and Hennet T (2010). HPLC and mass spectrometry analysis of dolichol-phosphates at the cell culture scale. Anal Biochem 396, 133-138.
39. Hillyard DZ, Jardine AG, McDonald KJ, and Cameron AJ (2004). Fluvastatin inhibits raft dependent Fcγ receptor signalling in human monocytes. Atherosclerosis 172, 219-228.
40. Zhuang L, Kim J, Adam RM, Solomon KR, and Freeman MR (2005). Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115, 959-968.
41. Maxfield FR and Tabas I (2005). Role of cholesterol and lipid organization in disease. Nature 438, 612-621.
42. Simons K and Ikonen E (2000). How cells handle cholesterol. Science 290, 1721-1726.
43. de Meyer F and Smit B (2009). Effect of cholesterol on the structure of a phospholipid bilayer. Proc Natl Acad Sci USA 106, 3654-3658.
44. Thorens B and Mueckler M (2010). Glucose transporters in the 21st century. Am J Physiol Endocrinol Metab 298, E141-E145.
45. Carruthers A, DeZutter J, Ganguly A, and Devaskar SU (2009). Will the original glucose transporter isoform please stand up! Am J Physiol Endocrinol Metab 297, E836-E848.
46. Baker M (2010). Making membrane proteins for structures: a trillion tiny tweaks. Nat Methods 7, 429-434.
47. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, et al. (2007). Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450, 383-387.
48. Hiller S, Garces RG, Malia TJ, Orekhov VY, Colombini M, and Wagner G (2008). Solution structure of the integral human membrane protein VDAC-1 in detergent micelles. Science 321, 1206-1210.
49. Epand RM, Thomas A, Brasseur R, and Epand RF (2010). Cholesterol interaction with proteins that partition into membrane domains: an overview. Subcell Biochem 51, 253-278.
50. Kurowski MA and Bujnicki JM (2003). GeneSilico protein structure prediction meta-server. Nucleic Acids Res 31, 3305-3307.
51. Kosinski J, Cymerman IA, Feder M, Kurowski MA, Sasin JM, and Bujnicki JM (2003). A "FRankenstein's monster" approach to comparative modeling: merging the finest fragments of fold-recognition models and iterative model refinement aided by 3D structure evaluation. Proteins 53(suppl 6), 369-379.
52. Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, and Yang W (2010). Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate 70, 971-981.